CD8A and Thrombocytopenia: Poor trials were found for ORR, DCR, QOL, myelosuppression, neutropenia, thrombocytopenia, anemia, gastrointestinal toxicity, liver toxicity, renal toxicity, neurotoxicity, CD3+ T cells, CD3+ CD4+ T cells, CD4+/CD8+ T cell ratios, and natural killer cells.